Back to Results

Nymox Pharmaceutical Corp (NYMXF)

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on research and development for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is being studied for benign prostatic hyperplasia, low-grade localized prostate cancer, and hepatocellular carcinoma. The company also markets NicAlert, a test used to determine smoking status, and TobacAlert, a test designed to detect exposure to second-hand smoke. In addition, Nymox is developing therapies aimed at the treatment and prevention of Alzheimer’s disease. Founded in 1989, the company is headquartered in Nassau, Bahamas. The listed security is common stock on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Free Cash Flow / Net Income
OTC-NYMX.F
Not available
Not available
Not available
Weak
0.0%
November 16, 2026
2.101 M
7.922 M
0.0%
52.4%
42.3%
Valuation • Fair Value

Nymox Pharmaceutical Corp (OTC-NYMX.F) Fair Value by Valuation Model

No usable valuation estimate is currently available for Nymox Pharmaceutical Corp (OTC-NYMX.F); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Nymox Pharmaceutical Corp (OTC-NYMX.F). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Nymox Pharmaceutical Corp (OTC-NYMX.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-3.551 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Nymox Pharmaceutical Corp (OTC-NYMX.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nymox Pharmaceutical Corp (OTC-NYMX.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

FCF / Net Income

42.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nymox Pharmaceutical Corp (OTC-NYMX.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nymox Pharmaceutical Corp (OTC-NYMX.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

10

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Nymox Pharmaceutical Corp (OTC-NYMX.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Nymox Pharmaceutical Corp (OTC-NYMX.F) Stock Forecast & Technical Outlook

Review Nymox Pharmaceutical Corp (OTC-NYMX.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nymox Pharmaceutical Corp (OTC-NYMX.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Nymox Pharmaceutical Corp (OTC-NYMX.F) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Nymox Pharmaceutical Corp (OTC-NYMX.F) Stock FAQ

Data-supported answers about Nymox Pharmaceutical Corp (OTC-NYMX.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Nymox Pharmaceutical Corp (OTC-NYMX.F). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Nymox Pharmaceutical Corp (OTC-NYMX.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nymox Pharmaceutical Corp (OTC-NYMX.F) is November 16, 2026.

The latest available data indicates no current dividend yield for Nymox Pharmaceutical Corp (OTC-NYMX.F).

The current market capitalization listed for Nymox Pharmaceutical Corp is 2.101 M.

The current enterprise value listed for Nymox Pharmaceutical Corp is 7.922 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nymox Pharmaceutical Corp is OTC-NYMX.F, and the stock is listed on OTC Markets.

Nymox Pharmaceutical Corp (OTC-NYMX.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Nymox Pharmaceutical Corp is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nymox Pharmaceutical Corp is 52.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B